Multiplex assays market is anticipated to grow at a CAGR of 14.8% during the forecast period (2023-2030). The market’s growth is attributed to the increasing advancements in immunotherapy. The increased use of immunotherapy, particularly chimeric antigen receptor (CAR) T cell therapy, for cancer treatment increases the need for accurate measurement and monitoring of CAR-T cells. Multiplex digital PCR assays satisfy the demand by delivering accurate, comprehensive analysis necessary for determining therapy success. For instance, in June 2023, BioPharma Services, Inc., launched new multiplex digital PCR assays for comprehensive quantification of multiple CAR-T cells, a type of cancer immunotherapy that involves genetically modifying T-cells to recognize and destroy certain cancers. The analysis is based on the Qiagen QIAcuity digital PCR methodology, that offers a powerful yet simple digital PCR experience with its unique nanoplate methodology.
Segmental Outlook
The global multiplex assays market is segmented on the type, technology, and end-user. Based on the type, the market is sub-segmented into protein multiplex assays, nucleic acid-based multiplex assays, and cell-based multiplex assays. Based on the technology, the market is sub-segmented into multiplex real-time PCR, luminex bead technology, flow cytometry, and others. Further, based on the end-user, the market is sub-segmented into pharmaceutical and biopharmaceutical companies, CROs, research and academic institutions, and others. Among the type, the nucleic acid-based multiplex assays subcategory is expected to capture a significant portion of the market share. This is attributed to the increase in the usage of nucleic acid-based multiplex assays and research on nucleic acid-based multiplex assays.
The Multiplex Real-Time PCR Sub-Segment is Anticipated to Hold a Considerable Share of the global Multiplex assays Market
Among the technology, the multiplex real-time PCR sub-segment is expected to hold a considerable share of the global multiplex assays market. The segmental growth is attributed to the enhanced testing efficiency. Multiplex assays simplify testing by detecting several targets in a single response. The capacity to recognize two N-gene target sequences in a single reaction decreases testing time, boosts throughput, and enhances diagnostic laboratory efficiency. For instance, in May 2020, Gold Standard Diagnostics Launched Multiplex Real-Time PCR Assay for SARS-CoV-2. GSD NovaPrime SARS-CoV-2 (COVID-19) is a real-time PCR test designed to detect SARS-CoV-2. It is a multiplex test which detects two target sequences of the N-gene in one reaction, providing results in 2 hours. The reagents include an extraction/ inhibition control and a positive control.
Regional Outlook
The global multiplex assays market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market around the globe, owing to the increasing number of individuals suffering from chronic and infectious diseases, in addition to increased awareness of the usage of multiplex assay products and services.
Global Multiplex Assays Market Growth by Region, 2023-2030
The North America Region is Expected to Grow at a Significant CAGR in the global Multiplex Assays Market
Among all regions, the North America region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the pandemic preparedness and surveillance. A primary driving element is the urgent need for precise and efficient serological assays to detect prior infections and track population exposure rates during the COVID-19 pandemic. Multiplex assays with high specificity and sensitivity, such as this serological assay, are essential in population-level surveillance. According to the National Institute of Health (NIH.gov), in January 2022, a serological COVID-19 multiplex assay was developed and validated using serum samples from 2 groups of recovered people; and those who had not yet been infected. After testing multiple potential antigens, the SARS-CoV-2 nucleocapsid protein (NP) and receptor-binding domain (RBD) of the spike protein were selected for the human COVID-19 multiplex assay. A comparison of synthesized and mammalian expressed RBD proteins showed the advantages of mammalian expression. Detection of NP and RBD specific IgG and IgA had excellent performance (AUC > 0.90) for distinguishing patients from controls, with the IgG assay having a wider dynamic range. This assay was used to evaluate seroprevalence to SARS-CoV-2 in people living in a low-incidence community in Ithaca, NY. Of the 332 healthy volunteers sampled 2020, 1.2-5.7% tested positive for either NP or RBD, which was higher than the county's reported incidence rate of 0.16%. This assay can be used to monitor community exposure rates and the duration of immune response following infection or vaccination.
Market Players Outlook
The major companies serving the global multiplex assays market include Bio-Rad Laboratories, Inc., Merck Group, PerkinElmer U.S. LLC, Quansys Biosciences Inc., Thermo Fisher Scientific Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2023, EDP Biotech merged with New Day Diagnostics to form a vertically integrated diagnostic company to advance the development and commercialization of diagnostic tests. EDP offers the ColoPlex in vitro diagnostic assay, that assists in the early detection of pre-cancerous cancer polyps and colorectal cancer.
The Report Covers
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.2. Abcam plc
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Agilent Technologies
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. BioMérieux SA
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Key Strategy Analysis
4. Market Segmentation
4.1. Global Multiplex Assays Market by Type
4.1.1. Protein Multiplex Assays
4.1.2. Nucleic Acid-Based Multiplex Assays
4.1.3. Cell-based Multiplex Assays
4.2. Global Multiplex Assays Market by Technology
4.2.1. Multiplex Real-Time PCR
4.2.2. Luminex Bead Technology
4.2.3. Flow Cytometry
4.2.4. Others (Next-Generation Sequencing (NGS), and Microarray Technology)
4.3. Global Multiplex Assays Market by End-User
4.3.1. Pharmaceutical and Biopharmaceutical Companies
4.3.2. Contract Research Organizations (CROs)
4.3.3. Research and Academic Institutions
4.3.4. Others (Biotechnology and Pharmaceutical Companies, and Clinical Diagnostics Labs)
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Bio-Rad Laboratories, Inc.
6.2. Bio-Techne Corp.
6.3. BioTools Inc.
6.4. CareDx, Inc.
6.5. Diasorin S.p.A.
6.6. Hologic, Inc.
6.7. Illumina, Inc.
6.8. Merck Group
6.9. Meso Scale Diagnostics, LLC
6.10. PerkinElmer U.S. LLC
6.11. Promega Corp.
6.12. QIAGEN GmbH
6.13. Quansys Biosciences Inc.
6.14. Randox Laboratories
6.15. Seegene, Inc.
6.16. Thermo Fisher Scientific Inc.
1. GLOBAL MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
2. GLOBAL PROTEIN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
3. GLOBAL NUCLEIC ACID-BASED MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
4. GLOBAL CELL-BASED MULTIPLEX ASSAYS RESEARCH MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
5. GLOBAL MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
6. GLOBAL MULTIPLEX ASSAYS BY MULTIPLEX REAL-TIME PCR MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
7. GLOBAL MULTIPLEX ASSAYS BY LUMINEX BEAD TECHNOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
8. GLOBAL MULTIPLEX ASSAYS BY FLOW CYTOMETRY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
9. GLOBAL MULTIPLEX ASSAYS BY OTHER TECHNOLOGIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
10. GLOBAL MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
11. GLOBAL MULTIPLEX ASSAYS FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
12. GLOBAL MULTIPLEX ASSAYS FOR CONTRACT RESEARCH ORGANIZATIONS (CRO) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
13. GLOBAL MULTIPLEX ASSAYS FOR RESEARCH AND ACADEMIC INSTITUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
14. GLOBAL MULTIPLEX ASSAYS FOR OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
15. GLOBAL MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
16. NORTH AMERICAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
17. NORTH AMERICAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
18. NORTH AMERICAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
19. NORTH AMERICAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
20. EUROPEAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
21. EUROPEAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
22. EUROPEAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
23. EUROPEAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
24. ASIA-PACIFIC MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
25. ASIA-PACIFIC MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
26. ASIA-PACIFIC MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
27. ASIA-PACIFIC MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
28. REST OF THE WORLD MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
29. REST OF THE WORLD MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
30. REST OF THE WORLD MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
31. REST OF THE WORLD MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
1. GLOBAL MULTIPLEX ASSAYS MARKET SHARE BY TYPE, 2022 VS 2030 (%)
2. GLOBAL PROTEIN MULTIPLEX ASSAYS MARKET SHARE BY REGION, 2022 VS 2030 (%)
3. GLOBAL NUCLEIC ACID-BASED MULTIPLEX ASSAYS MARKET SHARE BY REGION, 2022 VS 2030 (%)
4. GLOBAL CELL-BASED MULTIPLEX ASSAYS RESEARCH MARKET SHARE BY REGION, 2022 VS 2030 (%)
5. GLOBAL MULTIPLEX ASSAYS MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
6. GLOBAL MULTIPLEX ASSAYS BY MULTIPLEX REAL-TIME PCR MARKET SHARE BY REGION, 2022 VS 2030 (%)
7. GLOBAL MULTIPLEX ASSAYS BY LUMINEX BEAD TECHNOLOGY MARKET SHARE BY REGION, 2022 VS 2030 (%)
8. GLOBAL MULTIPLEX ASSAYS BY FLOW CYTOMETRY MARKET SHARE BY REGION, 2022 VS 2030 (%)
9. GLOBAL MULTIPLEX ASSAYS BY OTHER TECHNOLOGIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
10. GLOBAL MULTIPLEX ASSAYS MARKET SHARE BY END-USER, 2022 VS 2030 (%)
11. GLOBAL MULTIPLEX ASSAYS FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
12. GLOBAL MULTIPLEX ASSAYS FOR CONTRACT RESEARCH ORGANIZATIONS (CRO) MARKET SHARE BY REGION, 2022 VS 2030 (%)
13. GLOBAL MULTIPLEX ASSAYS FOR RESEARCH AND ACADEMIC INSTITUTIONS MARKET SHARE BY REGION, 2022 VS 2030 (%)
14. GLOBAL MULTIPLEX ASSAYS FOR OTHER END-USERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
15. GLOBAL MULTIPLEX ASSAYS MARKET SHARE BY REGION, 2022 VS 2030 (%)
16. US MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
17. CANADA MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
18. UK MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
19. FRANCE MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
20. GERMANY MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
21. ITALY MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
22. SPAIN MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
23. REST OF EUROPE MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
24. INDIA MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
25. CHINA MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
26. JAPAN MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
27. SOUTH KOREA MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
28. REST OF ASIA-PACIFIC MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
29. REST OF THE WORLD MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)